CA3066048A1 - Polytherapie - Google Patents
Polytherapie Download PDFInfo
- Publication number
- CA3066048A1 CA3066048A1 CA3066048A CA3066048A CA3066048A1 CA 3066048 A1 CA3066048 A1 CA 3066048A1 CA 3066048 A CA3066048 A CA 3066048A CA 3066048 A CA3066048 A CA 3066048A CA 3066048 A1 CA3066048 A1 CA 3066048A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- icos
- antigen binding
- binding portion
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne des procédés de traitement du cancer chez un patient en ayant besoin, le procédé comprenant l'administration au patient d'une quantité efficace d'un agent dirigé contre l'ICOS humain et d'une quantité efficace d'un agent dirigé contre PD-1 humain ou PD-Ll humain séquentiellement. L'invention concerne également un anticorps anti-ICOS ou un fragment de liaison à l'antigène de celui-ci et un anticorps anti-PD-1 ou un fragment de liaison à l'antigène de celui-ci pour une utilisation séquentielle dans le traitement du cancer chez un être humain qui en a besoin. L'invention concerne un anticorps anti-ICOS ou un fragment de liaison à l'antigène de celui-ci et un anticorps anti-PD-Ll ou un fragment de liaison à l'antigène de celui-ci pour une utilisation séquentielle dans le traitement du cancer chez un être humain qui en a besoin.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762517309P | 2017-06-09 | 2017-06-09 | |
US62/517,309 | 2017-06-09 | ||
US201862666278P | 2018-05-03 | 2018-05-03 | |
US62/666,278 | 2018-05-03 | ||
PCT/IB2018/054167 WO2018225033A1 (fr) | 2017-06-09 | 2018-06-08 | Polythérapie |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3066048A1 true CA3066048A1 (fr) | 2018-12-13 |
Family
ID=62873504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3066048A Pending CA3066048A1 (fr) | 2017-06-09 | 2018-06-08 | Polytherapie |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP3634483A1 (fr) |
JP (1) | JP2020522555A (fr) |
CN (1) | CN110869049A (fr) |
BR (1) | BR112019025325A2 (fr) |
CA (1) | CA3066048A1 (fr) |
WO (1) | WO2018225033A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116640214A (zh) | 2016-08-09 | 2023-08-25 | 科马布有限公司 | 分离抗体及其应用 |
WO2019122882A1 (fr) | 2017-12-19 | 2019-06-27 | Kymab Limited | Anticorps bispécifique pour icos et pd-l1 |
US20230140694A1 (en) * | 2020-04-14 | 2023-05-04 | GlaxoSmithKline Intellectual Property Developement Limited | Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies |
US20230149543A1 (en) * | 2020-04-14 | 2023-05-18 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer based upon an icos antbody and a pd-l1 antibody tgf-bets-receptor fusion protein |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
JP4212278B2 (ja) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
JP4488740B2 (ja) | 2001-11-13 | 2010-06-23 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | 免疫細胞活性化を調節する作用剤およびその使用方法 |
AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
AU2003288675B2 (en) | 2002-12-23 | 2010-07-22 | Medimmune Limited | Antibodies against PD-1 and uses therefor |
EP1591527B1 (fr) | 2003-01-23 | 2015-08-26 | Ono Pharmaceutical Co., Ltd. | Substance specifique a pd-1 humain |
CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
MX2007015942A (es) | 2005-07-01 | 2008-03-07 | Medarex Inc | Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada. |
US20080279851A1 (en) | 2007-05-07 | 2008-11-13 | Medlmmune, Llc | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
DK2170959T3 (da) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | Antistoffer mod human programmeret dødsreceptor pd-1 |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
AU2009288289B2 (en) | 2008-08-25 | 2012-11-08 | Amplimmune, Inc. | PD-1 antagonists and methods of use thereof |
JP5794917B2 (ja) | 2008-09-12 | 2015-10-14 | アイシス・イノベーション・リミテッドIsis Innovationlimited | Pd−1特異抗体およびその使用 |
AU2009290544B2 (en) | 2008-09-12 | 2015-07-16 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
CN102264762B (zh) | 2008-09-26 | 2018-03-27 | 达纳-法伯癌症研究公司 | 人抗pd‑1、pd‑l1和pd‑l2的抗体及其应用 |
EP2358392B1 (fr) | 2008-11-12 | 2019-01-09 | MedImmune, LLC | Formulation d'anticorps |
TWI686405B (zh) | 2008-12-09 | 2020-03-01 | 建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
WO2011041613A2 (fr) * | 2009-09-30 | 2011-04-07 | Memorial Sloan-Kettering Cancer Center | Immunothérapie combinée pour le traitement du cancer |
EP2504028A4 (fr) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | Inhibition simultanée de pd-l1/pd-l2 |
RS60033B1 (sr) | 2009-11-24 | 2020-04-30 | Medimmune Ltd | Ciljano vezujući agensi usmereni na b7-h1 |
US20110280877A1 (en) | 2010-05-11 | 2011-11-17 | Koji Tamada | Inhibition of B7-H1/CD80 interaction and uses thereof |
CN101898945B (zh) | 2010-07-27 | 2013-05-08 | 大连理工大学 | 盐析萃取发酵液中丙酮和丁醇的方法 |
EP2691419B1 (fr) | 2011-03-31 | 2016-11-09 | INSERM - Institut National de la Santé et de la Recherche Médicale | Anticorps dirigés contre icos et utilisation de ceux-ci |
KR102049817B1 (ko) | 2011-08-01 | 2019-12-02 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법 |
BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
US9212224B2 (en) | 2012-05-15 | 2015-12-15 | Bristol-Myers Squibb Company | Antibodies that bind PD-L1 and uses thereof |
KR20150023811A (ko) * | 2012-06-21 | 2015-03-05 | 컴퓨젠 엘티디. | 암의 치료를 위한 lsr 항체 및 그의 용도 |
WO2014033327A1 (fr) | 2012-09-03 | 2014-03-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anticorps anti-icos pour le traitement de la réaction greffe contre hôte |
CA2886433C (fr) | 2012-10-04 | 2022-01-04 | Dana-Farber Cancer Institute, Inc. | Anticorps monoclonaux humains anti pd-l1 et procedes d'utilisation |
EP3030322A2 (fr) * | 2013-08-05 | 2016-06-15 | Cambridge Enterprise Limited | Inhibition de la signalisation cxr4 en immunothérapie anticancéreuse |
MA41414A (fr) * | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
SG11201707769VA (en) | 2015-03-23 | 2017-10-30 | Jounce Therapeutics Inc | Antibodies to icos |
US20180230431A1 (en) * | 2015-08-07 | 2018-08-16 | Glaxosmithkline Intellectual Property Development Limited | Combination Therapy |
-
2018
- 2018-06-08 EP EP18739638.7A patent/EP3634483A1/fr not_active Withdrawn
- 2018-06-08 CA CA3066048A patent/CA3066048A1/fr active Pending
- 2018-06-08 BR BR112019025325-4A patent/BR112019025325A2/pt unknown
- 2018-06-08 JP JP2019567709A patent/JP2020522555A/ja active Pending
- 2018-06-08 CN CN201880044500.1A patent/CN110869049A/zh active Pending
- 2018-06-08 WO PCT/IB2018/054167 patent/WO2018225033A1/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CN110869049A (zh) | 2020-03-06 |
EP3634483A1 (fr) | 2020-04-15 |
JP2020522555A (ja) | 2020-07-30 |
BR112019025325A2 (pt) | 2020-06-23 |
WO2018225033A1 (fr) | 2018-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7325959B2 (ja) | 腫瘍特異的細胞の枯渇のための抗CD25 FCγ受容体二重特異性抗体 | |
JP2022065073A (ja) | Bcma結合分子及びその使用方法 | |
AU2015295946B2 (en) | Anti-PD-1 antibody and use thereof | |
JP2023130380A (ja) | Gprc5dキメラ抗原受容体及びそれを発現する細胞 | |
KR20190039421A (ko) | 항-tigit 항체, 항-pvrig 항체 및 이들의 조합 | |
CA3124168A1 (fr) | Anticorps anti-cd28 x anti-cd22 bispecifiques et leurs utilisations | |
CA3123420A1 (fr) | Anticorps anti-muc16 x anti-cd28 bispecifiques et leurs utilisations | |
Berezhnoy et al. | Development and preliminary clinical activity of PD-1-guided CTLA-4 blocking bispecific DART molecule | |
CA3066048A1 (fr) | Polytherapie | |
EP3494140A1 (fr) | Polythérapie à base d'anticorps anti-icos et anti-pd-1 | |
JP7383620B2 (ja) | 養子細胞療法およびチェックポイント阻害剤を使用する併用療法 | |
KR20200140315A (ko) | 항-cd27 항체 및 그의 용도 | |
CA3132198A1 (fr) | Polytherapies anticancereuses comprenant des agents de blocage de ctla-4 et pd-1 | |
CN115135344A (zh) | 在疗法中使用的抗体 | |
KR20220025739A (ko) | T-세포 활성화를 위한 항체 | |
WO2023285552A1 (fr) | Agents de liaison multispécifiques contre cd40 et cd137 en polythérapie du cancer | |
US20200181275A1 (en) | Combination therapy with icos agonist and ox40 agonist to treat cancer | |
US20200190194A1 (en) | Combination therapy | |
CN110662764A (zh) | 抗程序性死亡配体1(pd-l1)抗体及其治疗用途 | |
US20200190195A1 (en) | Combination therapy with icos agonist and ox40 agonist to treat cancer | |
WO2020086476A1 (fr) | Schéma posologique | |
WO2022268740A1 (fr) | Régime posologique combiné d'agents de liaison cd137 et pd-l1 | |
EA040773B1 (ru) | Анти-tigit антитела, анти-pvrig антитела и их комбинации |